Stocks
Edwards Lifesciences Financial Statements (EW) |
||||||||||
| Edwards Lifesciencessmart-lab.ru | % | 2020 | 2021 | 2022 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 12.02.2021 | 14.02.2022 | 31.12.2022 | 13.02.2023 | 12.02.2024 | 29.04.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 4 386 | 5 233 | 5 382 | 5 382 | 6 005 | 6 265 | |||
| Operating Income, bln rub | 1 628 | 1 349 | 1 749 | 1 749 | 1 534 | 1 676 | ||||
| EBITDA, bln rub | ? | 1 736 | 1 483 | 1 784 | 1 830 | 1 945 | 1 682 | |||
| Net profit, bln rub | ? | 823.4 | 1 503 | 1 522 | 1 522 | 1 402 | 1 444 | |||
| OCF, bln rub | ? | 1 054 | 1 732 | 1 218 | 895.8 | 30.4 | ||||
| CAPEX, bln rub | ? | 407.3 | 329.8 | 264.8 | 266.3 | 252.2 | ||||
| FCF, bln rub | ? | 647.0 | 1 402 | 953.4 | 629.5 | -221.8 | ||||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 1 989 | 2 397 | 2 513 | 2 513 | 2 895 | 3 051 | ||||
| Cost of production, bln rub | 1 081 | 1 249 | 1 080 | 1 080 | 1 380 | 1 482 | ||||
| R&D, bln rub | 760.7 | 903.1 | 945.2 | 945.2 | 1 072 | 1 110 | ||||
| Interest expenses, bln rub | 15.8 | 18.4 | 16.3 | 19.2 | 17.6 | 27.8 | ||||
| Assets, bln rub | 7 237 | 8 503 | 8 293 | 8 293 | 9 363 | 9 736 | ||||
| Net Assets, bln rub | ? | 4 574 | 5 836 | 5 807 | 5 807 | 6 650 | 7 118 | |||
| Debt, bln rub | 694.9 | 690.3 | 691.3 | 691.3 | 694.9 | 699.2 | ||||
| Cash, bln rub | 1 403 | 1 467 | 1 215 | 1 215 | 1 645 | 1 698 | ||||
| Net debt, bln rub | -707.7 | -776.5 | -524.0 | -524.0 | -949.6 | -998.4 | ||||
| Ordinary share price, rub | 91.2 | 129.6 | 74.6 | 74.6 | 76.3 | 65.5 | ||||
| Number of ordinary shares, mln | 622.6 | 623.3 | 619.0 | 619.0 | 606.7 | 601.6 | ||||
| Market cap, bln rub | 56 800 | 80 749 | 46 184 | 46 184 | 46 261 | 39 429 | ||||
| EV, bln rub | ? | 56 092 | 79 972 | 45 660 | 45 660 | 45 311 | 38 430 | |||
| Book value, bln rub | 3 070 | 4 344 | 4 357 | 4 357 | 4 968 | 5 418 | ||||
| EPS, rub | ? | 1.32 | 2.41 | 2.46 | 2.46 | 2.31 | 2.40 | |||
| FCF/share, rub | 1.04 | 2.25 | 0.00 | 1.54 | 1.04 | -0.37 | ||||
| BV/share, rub | 4.93 | 6.97 | 7.04 | 7.04 | 8.19 | 9.01 | ||||
| EBITDA margin, % | ? | 39.6% | 28.3% | 33.1% | 34.0% | 32.4% | 26.9% | |||
| Net margin, % | ? | 18.8% | 28.7% | 28.3% | 28.3% | 23.4% | 23.0% | |||
| FCF yield, % | ? | 1.14% | 1.74% | 0.00% | 2.06% | 1.36% | -0.56% | |||
| ROE, % | ? | 18.0% | 25.8% | 26.2% | 26.2% | 21.1% | 20.3% | |||
| ROA, % | ? | 11.4% | 17.7% | 18.4% | 18.4% | 15.0% | 14.8% | |||
| P/E | ? | 69.0 | 53.7 | 30.3 | 30.3 | 33.0 | 27.3 | |||
| P/FCF | 87.8 | 57.6 | 48.4 | 73.5 | -177.8 | |||||
| P/S | ? | 12.9 | 15.4 | 8.58 | 8.58 | 7.70 | 6.29 | |||
| P/BV | ? | 18.5 | 18.6 | 10.6 | 10.6 | 9.31 | 7.28 | |||
| EV/EBITDA | ? | 32.3 | 53.9 | 25.6 | 25.0 | 23.3 | 22.8 | |||
| Debt/EBITDA | -0.41 | -0.52 | -0.29 | -0.29 | -0.49 | -0.59 | ||||
| R&D/CAPEX, % | 186.8% | 273.8% | 356.9% | 402.5% | 440.3% | |||||
| CAPEX/Revenue, % | 9.29% | 6.30% | 0.00% | 4.92% | 4.43% | 4.03% | ||||
| Edwards Lifesciences shareholders | ||||||||||
